Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
ACTH (4-10) Analogs
Overview
ACTH (4-10) analogs are synthetic peptides derived from the 4 to 10 amino acid sequence of adrenocorticotropic hormone, engineered to preserve neurotrophic and cognitive-enhancing properties while eliminating steroidogenic activity. These fragments are thought to influence attention, memory consolidation, and synaptic plasticity through melanocortin receptor interactions and modulation of neurotransmitter systems.
Mechanism of Action
They represent a class of nootropic peptides explored since the 1970s.
Research Summary & Key Findings
Early clinical studies in the 1970s and 1980s, published in psychopharmacology journals, reported improvements in attention and memory in healthy volunteers and patients with cognitive impairment. Subsequent research has been limited, and no ACTH fragment analogs have achieved regulatory approval for cognitive indications. Interest has been renewed in recent years for potential applications in ADHD and age-related cognitive decline.
Clinical Status
ACTH (4-10) Analogs is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "ACTH Analogs"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "ACTH Analogs"
Registered interventional and observational studies, including status and phase.
- PubChem: "ACTH Analogs"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cognitive
Semax
InvestigationalA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsNo lawful pathway today
ACTH (4-10) Analogs is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.